References
Anand, R., Gill, K., Mahdi, A. (2014). Therapeutics of Alzheimer’s disease: Past, present, and future. Neuropharmacology, 76(A), 27-50. http://doi.org/10.1016/j.neuropharm.2013.07.004
Banerjee, S., Hellier, J., Romeo, R., Dewey, M., Knapp, M., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., Lawton, J., Lindesay, G., Livingston, N., McCrae, E., Moniz-Cook, J., Murray, S., Nurock, J., Orrell, M., O’Brien, M., Poppe, A., Thomas, R., Walwyn, K., Wilson, A. (2013). Study of the use of antidepressants for depression in dementia: the HTA-SADD trial-a multicentre, randomized, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technological Assessment, 17, 1-166. http://dx.doi.ord/10.3310/hta17070
Braskie, M. N., Klunder, A. D., Hayashi, K. M., Protas, H., Kepe, V., Miller, K. J., … Thompson, P. M. (2010). Plaque and tangle imaging and cognition in normal aging and Alzheimer’s disease. Neurobiology of Aging, 31(10), 1669–1678. http://doi.org/10.1016/j.neurobiolaging.2008.09.012
Carlson, N. R., & Birkett, M. A. (2017). Physiology of Behavior. Pearson.
Hampel H., Prvulovic D., Teipel S, Jessen F., Luckhaus C., Frolich L., Riepe MW., Dodel R., Leyhe T., Bertram L., Hoffmann W., Faltraco F. (2011). “The future of Alzheimer’s disease: the next 10 years.” Prog Neurobiol 95(4):718–728
Hardy, J., & Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends in Pharmacological Sciences, 12(10), 383-388. https://doi.org/10.1016/0165-6147(91)90609-V
King, M.V., & Marsden, K. C. (2008) A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends in Pharmacological Science, 29. 482-492.
Lott, I., & Head, E. (2004). Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiology of Aging, 26(3), 383-389. https://doi.org/10.1016/j.neurobiolaging.2004.08.005
Kivipelto, E.L. Helkala, M.P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, H. Soininen, J. Tuomilehto, A. Nissinen. (2001) “Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study.” BMJ, 322, pp. 1447–1451
Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current
Drugs work in Alzheimer’s disease? CNS Neurosci Ther. 2010 Aug;16(4):235-45. https://doi.org/10.1111/j.1755-5949.2010.00175.x
Mudher, A., & Lovestone, S. (2002). Alzheimer’s disease – do tauists and baptists finally shake hands? Trends in Neuroscience, 25(1), 22-26. https://doi.org/10.1016/S0166-2236(00)02031-2
Lee, H., Perry, G., Moreira, P., Garrett, M., Liu, Q., Zhu, X., Takeda, A., Nunomura, A., Smith, R. (2005). “Tau phosphorylation in Alzheimer’s disease: pathogen or protector?” Cell Press, 4(11): 164-169
Pulawski, W., Ghoshdastider, U., Andrisano, V., & Filipek, S. (2012). Ubiquitous Amyloids. Applied Biochemistry and Biotechnology, 166(7), 1626–1643. http://doi.org/10.1007/s12010-012-9549-3
Sadigh-Eteghad S, Talebi M, Farhoudi M, EJ Golzari S, Sabermarouf B, Mahmoudi J (2014). “Beta-amyloid exhibits antagonistic effects on alpha 7 nicotinic acetylcholine receptors in orchestrated manner”. Journal of Medical Hypotheses and Ideas, 8: 48–52.
Vellas, B., Black, R., Thal, L. J., Fox, N. C., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., Grundman, M. (2009). Long-term follow-up of patients immunized with AN1782: reduced functional decline in antibody responders. Current Alzheimer’s Research, 6, 144-151. http://doi.org/10.2174/156720509787602852
Wilson, R. S., Barral, S., Lee, J. H., Leurgans, S. E., Foroud, T. M., Sweet, R. A., … Bennett, D. A. (2011). Heritability of Different Forms of Memory in the Late Onset Alzheimer’s Disease Family Study. Journal of Alzheimer’s Disease : JAD, 23(2), 249–255. http://doi.org/10.3233/JAD-2010-101515
